Merck to Test Promising HIV Vaccines Using NIAID Network
BETHESDA, Maryland-Merck & Co. will use a worldwide research network organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID) to test promising HIV vaccines it develops.
BETHESDA, MarylandMerck & Co. will use a worldwide research network organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID) to test promising HIV vaccines it develops.
The agreement will enable Merck to evaluate its vaccines in a collaborative effort with the international HIV Vaccine Trials Network (HVTN), which consists of centers at 12 US academic sites and 13 institutions in Africa, Asia, South America, and the Caribbean.
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
